Literature DB >> 12858324

Topiramate in benzodiazepine withdrawal.

Michel Cheseaux1, Martine Monnat, Daniele F Zullino.   

Abstract

There is an increasing interest in anticonvulsants for the treatment of benzodiazepine withdrawal symptoms. The new anticonvulsant compound topiramate seems to be an especially promising drug for this indication. It acts, among others, as an AMPA antagonist, which may be responsible in part for its anticonvulsant efficacy, but may also modulate the withdrawal-induced activation of noradrenergic neurons in the locus coeruleus, which are related to some behavioural effects of benzodiazepine withdrawal. A case is presented of a rapid benzodiazepine-withdrawal treated successfully with topiramate. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12858324     DOI: 10.1002/hup.497

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  5 in total

1.  Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers.

Authors:  Mehmet Sofuoglu; James Poling; Maria Mouratidis; Thomas Kosten
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

Review 2.  Topiramate in the treatment of substance-related disorders: a critical review of the literature.

Authors:  Ann K Shinn; Shelly F Greenfield
Journal:  J Clin Psychiatry       Date:  2010-03-09       Impact factor: 4.384

Review 3.  Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2021-01-03       Impact factor: 2.953

4.  Topiramate in the treatment of compulsive sexual behavior: case report.

Authors:  Yasser Khazaal; Daniele Fabio Zullino
Journal:  BMC Psychiatry       Date:  2006-05-23       Impact factor: 3.630

Review 5.  Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation.

Authors:  Dimy Fluyau; Neelambika Revadigar; Brittany E Manobianco
Journal:  Ther Adv Psychopharmacol       Date:  2018-02-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.